Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
M.D. Anderson Cancer Center
BicycleTx Limited
Maastricht University Medical Center
Incyte Corporation
Exelixis
Compugen Ltd
Incyte Corporation
Duke University
MultiVir, Inc.